Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Core Insights - ARS Pharmaceuticals, Inc. has published findings indicating that approximately 90% of patients experiencing anaphylaxis were effectively treated with a single dose of neffy, a nasal spray formulation of epinephrine [1][2][4] - The real-world effectiveness of neffy aligns closely with historical data for epinephrine injections, suggesting clinical interchangeability between the two treatment methods [2][4] Group 1: Clinical Performance of Neffy - A total of 545 patients were treated with neffy during oral food challenges and allergen immunotherapy, with a success rate of 89.2% for a single dose administered by healthcare providers [2][9] - Meta-analyses show a similar success rate of 88.9% for epinephrine injections, reinforcing the effectiveness of neffy in real-world settings [2][4] - Previous clinical studies, including a Phase 3 trial, indicated that no patients required a second dose of neffy for initial anaphylactic reactions [3][10] Group 2: Neffy Experience Program - The neffy experience program involved healthcare providers administering neffy to patients experiencing anaphylaxis symptoms, with data collected from 301 providers [8][9] - The program provided six doses of neffy for emergency use, with the labeling indicating that a second dose may be necessary if symptoms persist after five minutes [8][9] - The ongoing program now includes both 2 mg and 1 mg doses of neffy, expanding treatment options for patients [9] Group 3: Company Overview - ARS Pharmaceuticals is focused on empowering at-risk patients and caregivers to manage allergic reactions that could lead to anaphylaxis [21] - Neffy is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients aged 4 years and older who weigh at least 33 lbs [11][12] - The company aims to address limitations associated with traditional epinephrine auto-injectors, such as needle fear and portability issues, by offering a needle-free alternative [20][21]